Understanding the result of CATIE in the context of the field

CNS Spectrums

Volumn 11, Issue SUPPL. 7, 2006, Pages 40-47

  Glick, Ira D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIPID; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; LONG TERM CARE; META ANALYSIS; METABOLIC DISORDER; METHODOLOGY; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA;

EID: 33746504864     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900026675     Document Type: Article

References (27)

1. Lieberman JA, Stroup TS, McEvoy JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
2. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia design and protocol development. Schizophr Bull. 2003;29(1):15-31.
3. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160(7):1209-1222.
4. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361(9369):1581-1589.
5. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564.
6. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomized antipsychotic drug trials. Psychopharmacology. 2001;155(3):230-233.
7. Geddes J, Freemantle N, Harrison P, Bebbington P, for the National Schizophrenia Guideleine Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371-1376
8. Geddes J. Generalizing evidence to inform policy and practice: the example of the second generation "atypical" antipsychotics. Schizophr Bull. 2003;29:105-114.
9. IMS Health. Atypical antipsychotics: generating evidence to inform policy and practice. Available at: http://research.imshealth.com/ research_schizophrenia.htm. Accessed: February 14, 2006.
10. Harrington C, Gregorian R, Gemmen E, et al. Access and utilization of new anti-depressant and antipsychotic medications. Falls Church, Va.: Lewin Group, 2000. Available at: http://aspe.hhs.gov/search/health/reports/Psychmedaccess/ index. htm#TOC. Accessed: February 21, 2006.
11. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290(12):1624-1632.
12. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. Schizophr Bull. 2003;29(1):33-43.
13. Collins EJ, Hogan TP, Desai H. Measurement of therapeutic response in schizophrenia. A critical survey. Schizophr Res. 1991;5(3):249-253.
14. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196-201.
15. Meltzer HY. Interpreting the efficacy findings in CATIE: what clinicians should know. CNS Spectr. 2006;11(7 suppl 7):14-24.
16. Kane JM. Commentary on the clinical antipsychotic trials of intervention effectiveness (CATIE). J Clin Psychiatry. 2006;67(5):831-832.
17. Weeks M. NIMH study to guide treatment choices for schizophrenia [Medical News Today Web site]. September 20, 2005. Available at: http://www. medicalnewstoday.com/medicalnews.php?newsid=30861. Accessed: March 3, 2006
18. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipyschotic. Am J Psychiatry. 2006;163:611-622.
19. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
20. Keefe R, Bilder RM, Harvey PD, et al. Neurocognitive effects of antipsychotic medications in patient with chronic schizophrenia in the CATIE trial. Presented at: the 61st Annual Convention of the Society of Biological Psychiatry; May 18-20, 2006; Toronto, Canada. Abstract #311.
21. Davis JM, Chen N, Glick ID. Web supplement: a meta-analysis of the efficacy of second-generation antipsychotics. Available at: http://www.psych. uic.edu/faculty/davis/meta_analysis.pdf. Accessed March 26, 2006.
22. Martin JLR, Pérez V, Sacristán M, Rodríguez-Artalejo F, Martínez C, Álvarez E. Meta-analysis of drop-out rates in randomized clinical trials, comparing typical and atypical ntipsychotics in the treatment of schizophrenia. Eur Psychiatry. 2006;21(1):11-20.
23. Fleischhacker WW, Widschwendter CG. Treatment of schizophrenia patients: comparing new generation antipsycotics to each other. Curr Opin Psychiatry. 2006;19(2):128-134.
24. Koyanagi C, Forquer S, Alfano E. Medicaid policies to contain psychiatric drug costs. Health Aft 2005;24(2):536-544.
25. Hamann J, Langer B, Leucht S, Busch R, Kissling W. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry. 2004;161(7):1301-1304.
26. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334-1349.
27. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66(2):183-194.